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Abstract 
The  management  of  chronic  myelogenous
leukemia during pregnancy requires balancing
the well-being of the mother with that of the
fetus. We report a case of a 26-year-old lady
who was diagnosed with chronic myelogenous
leukemia  (CML)  at  15  weeks  gestation  and
who  had  an  atypical  chromosome  t(9;22;11)
(q34;q11.2;q13)  translocation.  She  was
observed through the remainder of the preg-
nancy and the disease remained stable; she
delivered a normal boy. Treatment with ima-
tinib mesylate was initiated shortly after deliv-
ery  and  she  went  into  molecular  complete
remission. We discuss the course of the dis-
ease  and  suggest  guidelines  for  managing
pregnancy with respect to the currently avail-
able agents imatinib, dasatinib and nilotinib.
Introduction
Chronic myelogenous leukemia (CML) is a
clonal  proliferation  of  progenitor  blast  cells,
resulting  from  a  reciprocal  translocation
between the long arms of chromosomes 9 and
22. The chimeric BCR-ABL fusion protein syn-
thesized from this translocation has tyrosine
kinase  activity  that  activates  a  number  of
intracellular proteins and is felt to be responsi-
ble for the disease. Until recent years no effec-
tive therapy has been available for CML and
patients typically died within 6 years of diagno-
sis.1 Hydroxyurea was of some value in reduc-
ing peripheral blood counts, but had no effect
on the bone marrow blast count. In the 1980s
interferon alpha (IFN-a) was shown to reduce
the number of marrow blast progenitor cells
and to induce partial remissions. More recent-
ly imatinib mesylate, an inhibitor of the BCR-
ABL  tyrosine  kinase,  has  made  dramatic
changes in the therapeutic approach to CML.
Two newer congeners, desatinib and nilotinib
are now also available and others are under
development. At the same time the use of tyro-
sine kinase inhibitors (TKIs) during pregnan-
cy presents problems. Here we discuss the case
of a 26-year-old lady who presented with CML
expressing  an  atypical  t(9;22;11)
(q34;q11.2;q13) chromosome translocation at
gestational age 15 weeks. The management of
CML in pregnancy is considered with respect
to all of the currently available tyrosine kinase
inhibitors.
Case Report
A 26-year-old white female in her 15th week
of  gestation  was  referred  to  hematology  for
evaluation of an elevated white cell count. At
initial evaluation her CBC showed WBC 18100
cells/mm3, hemoglobin 11.8 g/dL, Hct 36% and
platelets  562,000/mm3.  MCV  was  95.
Differential  was  87%  polymorphonuclear
leukocytes, 10% lymphocytes, 1% monocytes,
1% eosinophils and 1% basophils. Other labo-
ratory studies, including electrolytes and liver
function tests, were entirely normal. Leukocyte
alkaline  phosphatase  was  normal.  Physical
examination was unremarkable except for a 15
week pregnancy. FISH cytogenetics showed a
BCR-ABL fusion in 50.2% of the nuclei exam-
ined  and  metaphase  cytogenetics  confirmed
an atypical BCR-ABL translocation t(9;22;11)
(q34;q11.2;q13). Because of the pregnancy and
also her relatively low white cell count, a deci-
sion was made to observe her closely and to
postpone bone marrow examination. Her preg-
nancy proceeded uneventfully and her white
count did not rise. The highest white cell count
observed before delivery was 18,500 cells/mm3
and  the  highest  platelet  count  was  562,000
mm.3 In May, 2006 she delivered a normal boy
at term. His peripheral blood cytogenetics were
completely  normal,  46XY.  A  bone  marrow
examination on the patient was performed 2
weeks after delivery and showed morphology
consistent  with  chronic  myelogenous
leukemia. She was counseled about the use of
imatinib mesylate in pregnancy and elected to
undergo tubal ligation, as she already had two
normal children. She was started on imatinib
mesylate 400 mg daily. Six months later RT-
PCR analysis for BCR-ABL showed no amplifi-
able  mRNA  with  the  translocation.  She  has
remained  in  molecular  complete  remission
ever since. The most recent RT-PCR exam was
in 04/2011.
Materials and Methods
Bone  marrow  samples  were  processed  at
Mayo Clinic Laboratories for cytogenetic analy-
sis, FISH and quantitative RT-PCR.
Results
This patient exhibited a complex three-way
translocation in each metaphase from the chro-
mosome  study,  t(9;22;11)(q34;q11.2;q13).  The
gene/gene  region  involved  on  chromosome
11q13 is unknown. This complex translocation
still resulted in a typical Philadelphia chromo-
some,  which  demonstrated  typical  BCR/ABL
fusion.  This  implies  that  the  tyrosine  kinase
binding site also had the typical structure asso-
ciated with CML. While the chromosome studies
indicated  an  apparently  balanced  three-way
translocation based on the banding pattern, the
FISH  results  indicated  there  was  concurrent
deletion on the abnormal chromosome 9, result-
ing in a deletion of the residual ABL gene signal
and a deletion of the ASS gene at 9q34. In addi-
tion, a deletion of the portion of the BCR gene
that was supposed to translocate to chromosome
11q13  was  also  observed  by  the  FISH  test.
Clinically this patient had a relatively low eleva-
tion  in  WBC  count  for  CML  at  presentation.
Furthermore her WBC count did not change sig-
nificantly during her pregnancy and the disease
followed a stable and somewhat indolent course
over  that  period.  This  greatly  simplified  her
management. After she delivered and was placed
on imatinib mesylate, she went into complete
molecular remission in 6 months. This repre-
sents a 6 log reduction in the number of neoplas-
tic  cells,  estimating  that  1012 cells  existed  at
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presentation and 106 were present in molecular
complete remission.2This raises the question of
whether the inclusion of the fragment of chro-
mosome 11 in any way contributed to the slow
progression of the disease.
Discussion
Clinical progression of case
The  development  of  tyrosine  kinase
inhibitors has markedly changed the prognosis
of patients with CML. With the currently avail-
able drugs, survivals in excess of six years are
common. The incidence of CML in pregnancy
is  1-2  per  100,000  pregnancies/year.3,4
Although  most  patients  carry  the  t(9;22)
translocation, atypical translocations are found
in approximately 5-8% of cases.5,6 It is plausi-
ble  that  those  variations  could  affect  the
course of the disease by altering the structure
of  the  tyrosine  kinase  ligand  binding  site.
Several  authors  have  reported  atypical
t(9;22;11)  translocations  in  CML  and  some
have commented on the clinical course of the
disease  associated  with  the  translocation.6,7
Gahrton et al. noted in 1977 that a patient was
alive 10 months after diagnosis on busulfan
therapy.8 In 1985, Sessarego et al.6 described
four cases of variant Philadelphia chromosome
translocations in CML. Cytogenetic analysis of
one case revealed a complex three-way translo-
cation  t(9;11;22)(q34;q13;q11).  The  disease
eventually  progressed  to  blast  crisis.  The
unusual  translocation  did  not  change  either
the expected survival or the course of the dis-
ease. However, Belli et al.7 reported a variant
translocation t(9;22;11)(q34;q11.2;p15) inv(9)
(p13q34) without progression to an accelerat-
ed phase after 7 years. The present case pro-
vides a somewhat more detailed description of
the clinical disease features associated with a
similar translocation. CML in pregnancy has
been  the  subject  of  previous  discussions.9
Questions that arise include: i) how women
whose CML is diagnosed in pregnancy should
be managed; ii) whether women who are on
treatment with tyrosine kinase inhibitors for
CML  should  become  pregnant;  iii)  whether
there is a risk of fetal damage if the sexual
partner of a normal woman is being treated for
the disease, and iv) whether women who are
taking  tyrosine  kinase  inhibitors  should
breastfeed.    These  questions  have  been
addressed for imatinib mesylate,9-17 but a dis-
cussion  including  dasatinib  and  nilotinib  is
now  pertinent.  An  algorithm  relating  to  the
issues discussed is presented in Figure 1. 
Management of Chronic myeloge-
nous leukemia diagnosed during
pregnancy
Pregnancy does not alter the natural course
of CML. Appropriate management of pregnant
patients  with  CML  requires  attention  to  the
health of both mother and fetus. The risks to
the mother are rapid progression of the dis-
ease and thrombotic events, while those to the
fetus  involve  exposure  to  potentially  terato-
genic tyrosine kinase inhibitors, fetal prema-
turity, placental insufficiency and subnormal
birth  weight.9 Successful  pregnancies  have
been reported with close observation, leuka-
pheresis,  hydroxyurea,  IFN-a,  and  tyrosine
kinase inhibitors.3,4,18-29
Imatinib mesylate and its congeners dasa-
tinib and nilotinib have a potent effect on pro-
gression of CML and have improved overall dis-
ease survival. Animal studies suggest that ima-
tinib  has  teratogenic  effects.9 Imatinib  was
found to cause fetal abnormalities, including
decreased birth weight, abortion and mortality
in  rats  and  rabbits  at  exposures  lower  than
those expected in humans.9 Nilotinib was not
considered teratogenic in these systems.30 Pye
et al.31 evaluated the effects of imatinib in 180
women exposed to the drug during pregnancy.
Outcomes  were  available  for  125  women,  of
whom 50% delivered healthy infants. Twelve
pregnancies  resulted  in  fetal  abnormalities.
Cole et al.19 reviewed the cases of women who
became pregnant while on imatinib therapy.
Complications  included  low  birth  weight,
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Figure 1. Algorithm for chronic myelogenous leukemia treatment during pregnancy. [page 88] [Hematology Reports 2011; 3:e27]
hypospadias, meningocele, premature closure
of skull sutures, pyloric stenosis, exomphalos
and  kidney  abnormalities.  These  findings
emphasize  the  teratogenicity  of  imatinib
mesylate and by extension seem to apply to
dasatinib and nilotinib. In humans, they have
all  been  classified  as  pregnancy  category  D
drugs, which means that there is evidence of
fetal adverse reactions, but potential drug ben-
efits could warrant use during pregnancy.  We
conclude that continuing these drugs during
pregnancy is undesirable, and that although
normal pregnancies can occur, the risk of fetal
abnormalities is unacceptably high. 
Various alternatives to the use of TKIs in
this situation exist. The optimal approach is
close clinical observation for suitable patients.
This  includes  the  subset  of  asymptomatic
patients  with  laboratory  values  close  to  the
normal range. Cole et al.19 reported a 21-years-
old female who was diagnosed with CML in
early pregnancy. A decision was made to follow
her closely during the course of the pregnancy
and she delivered a normal baby. Therapy with
dasatinib was initiated 4 weeks after delivery.
In the present case the patient was monitored
closely throughout the duration of her preg-
nancy and delivered a normal boy with normal
chromosomes. 
If clinical observation is not feasible, it may
be possible to control peripheral white counts
with  leukapheresis.  This  method  has  been
widely advocated as the treatment of choice for
patients at or near the first trimester to rapid-
ly decrease WBC counts and to control high
risks  of  vascular  occlusion.26,32 An  obvious
advantage to leukapheresis is that it avoids the
teratogenic effects of drug administration.25-
28,33 Some authors propose that leukapheresis
can be used as a treatment throughout preg-
nancy.26,28 It can lead to hemodynamic instabil-
ity,  but  this  can  be  controlled  with  care  in
administration. If cytoreductive drugs are nec-
essary, the two leading candidates are IFN-a
and hydroxyurea. Of the two, IFN-ais the more
desirable.  It  does  not  inhibit  DNA  synthesis
directly and it crosses the placenta to a mini-
mal  extent4,29,32 Many  references  describe
administration  of  IFN-a during  pregnan-
cy.4,22,29,32,34,35 All  pregnancies  resulted  in
healthy babies without congenital abnormali-
ties. Interferon is relatively safe in pregnancy
and could be considered a drug of choice.32,34 A
limitation to its use  could be its relatively long
period of onset to maximum effect. However, it
could be used in combination with leukaphere-
sis. A number of cases of hydroxyurea admin-
istration during pregnancy have been report-
ed.23,24,36 The drug has teratogenic effects both
in animals36 and in humans. Robinet et al.36
examined pregnancy outcomes in 31 women
exposed to hydroxyurea. Malformations such
as hip dysplasia, unilateral renal dilatation and
pilonidal sinus were observed; the causal rela-
tionship  was  unclear.  These  malformations
could be regarded as minor but are still greater
in frequency than with interferon a.  
Should women who are being
treated with a TKI become preg-
nant?     
At this point in time, treatment of CML with
imatinib or other TKIs commits a patient to a
lifetime of therapy. No good guidelines exist
for discontinuation of the drug, except in the
context  of  a  clinical  trial.  Even  patients  in
major molecular remission may have 104-106
residual neoplastic bone marrow cells which
are sources of possible relapse although they
are below the level of detection by PCR ampli-
fication. Relapse after discontinuing imatinib
mesylate  may  be  followed  by  failure  to  re-
achieve  remission  when  the  drug  is
resumed.32This raises the question of whether
a patient in complete remission, even major
molecular remission, on imatinib or another
TKI, should become pregnant. The primary rec-
ommendation for all three of these drugs is to
avoid  pregnancy,  and  if  a  woman  becomes
pregnant,  the  drug  should  be  discontinued.
She should be clearly apprised of the issues
and be followed by a hematologist familiar with
this type of situation and its implications. It is
not clear at this point if the teratogenic risk of
TKIs extends throughout the entire pregnancy.
They should certainly be avoided during the
organ-forming period of the first and mid-sec-
ond trimesters. If a pregnant woman in com-
plete  remission  has  had  imatinib  discontin-
ued,  the  drug  will  be  held  so  long  as  she
remains in complete remission and would be
restarted after delivery. If she showed evidence
of  relapse,  then  attempts  would  be  made  to
delay re-initiation until at least the 6th month.
The alternatives of leukapheresis, hydroxyurea
and  IFN-a remain  possibilities  and  can  be
used on an individualized basis. These consid-
erations apply to all three drugs. 
Data on the use of nilotinib in pregnancy
are  limited.  Conchon  et  al.3 reported  a  30-
years-old female with CML whose second preg-
nancy was identified at 7.4 weeks of gestation,
while she was on 200 mg of nilotinib; treat-
ment was discontinued during the remainder
of her pregnancy. A healthy infant was deliv-
ered without complications. After delivery the
patient lost molecular, cytogenetic and hema-
tologic remission and was started on dasatinib.
The authors nonetheless concluded that if a
patient becomes pregnant while on nilotinib,
the drug should be discontinued. 
Conchon et al.18 described a case of an 18-
years-old female who became pregnant while
in hematologic remission on dasatinib thera-
py. The pregnancy was discovered during the
first trimester of gestation (after 4 weeks of
amenorrhea). Dasatinib treatment was discon-
tinued. The patient relapsed during pregnancy
and was treated with IFN-a without complete
hematologic response. She delivered a healthy
infant  without  any  abnormalities  detected
through  8  months  of  age.  This  patient  was
exposed to the drug 8 weeks post conception,
during the critical period of embryogenesis.  
We conclude that although cases of success-
ful  pregnancies  have  been  reported  with
patients on each of these drugs, the elevated
teratogenic risk remains. To the extent possi-
ble,  women  on  treatment  with  these  TKIs
should not become pregnant. Any drugs of this
class  should  be  discontinued  in  a  woman
found to be pregnant and the patient should be
observed  until  either  the  pregnancy  is  com-
plete or the disease starts to progress.  
If the sexual partner of an unaf-
fected woman is taking a TKI, 
will it affect the pregnancy? 
Several  reports  of  successful  pregnancies
conceived  by  men  taking  imatinib  mesylate
exist.11,12,37 These authors report a total of 19
pregnancies conceived from 17 men. Eighteen
of these resulted in normal children, without
birth defects and one ended in a spontaneous
abortion.  Examination  of  the  sperm  in  two
patients did not reveal an effect on its motility
or count.37 A single recent report has described
a male taking dasatinib who fathered a healthy
baby.38 In  preclinical  experiments  utilizing
drug doses five times higher than those used
in humans, nilotinib has not been shown to
affect  sperm  count,  motility  or  fertility  in
rats.30We conclude that at this time there is no
convincing evidence that treatment of a male
sexual  partner  with  imatinib  mesylate  pro-
duces a deleterious effect on pregnancy out-
comes.
Should women taking TKIs breast
feed infants?
A  final  question  regarding  perinatal  drug
exposure  is  whether  women  taking  TKIs
should breast feed. The data on that subject
pertain mostly to imatinib mesylate. Imatinib
is known to be secreted in breast milk.10,13-15
The literature on women who breast fed while
taking imatinib is very limited. In one case of
a  woman  who  breast  fed  no  adverse  effect
occurred in the newborn.13 Concentrations of
the drug and its metabolites were measured in
both plasma and breast milk. Plasma steady
state  concentrations  were  approximately  3.0
mcg/mL and 1.0 mcg/mL between 1 and 9 hours
after oral administration of 400 mg of the drug.
Concentrations in breast milk were between
1.1  and  1.4  mcg/mL.  The  authors  concluded
that  mothers  with  CML  could  safely  breast
feed. Other reports have focused on the excre-
tion of imatinib in breast milk.10,14,15 Ali et al.10
reported a 27-years-old female who was treated
with imatinib from the 21st to the 39th weeks of
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gestation.  The  infant  was  a  healthy  male.
Imatinib  was  detected  in  the  umbilical  cord
blood,  the  infant’s  peripheral  blood  and  the
mother’s  breast  milk.  Two  other  reports14,15
have  shown  very  similar  results.  No  human
data are available for nilotinib and dasatinib.
However,  one  study  demonstrated  nilotinib
transfer into the milk of lactating rats after
administration  of  a  dose  of  20  mg/kg.39 It
seems likely, although it is not yet proven, that
these  drugs  would  also  be  transferred  into
human  milk.  Many  sources  recommend
against breast feeding, but it is not possible at
this time to make a definitive statement about
whether  the  low  levels  to  which  an  infant
would be exposed are truly harmful.
Conclusions
Pregnancy in CML is an infrequent, but real
problem. The number of agents available for
the treatment of CML is increasing. The data
regarding teratogenicity and abortion rates in
patients treated with these drugs are incom-
plete. Based on the review of the existing data
certain generalizations tend to appear. All of
these drugs have some teratogenic potential
and  possibly  some  abortificient  potential  as
well. To the extent possible, their use should
be avoided during the organ forming period of
the first five months of pregnancy. If treatment
is necessary, leukapheresis or IFN-a alone or
in combination appears to be the safest. The
same considerations apply to a female who is
already  on  imatinib  and  wishes  to  become
pregnant. If at all possible, pregnancy should
be  avoided.  Based  on  the  limited  evidence
available, men who are on imatinib mesylate
would  be  able  to  safely  conceive  children.
Imatinib is clearly excreted in human breast
milk. It is not clear that these levels pose a risk
to  the  child,  but  if  possible  breast  feeding
should be avoided. The same applies to dasa-
tinib and nilotinib, but the data are very limit-
ed. Continued attention to this problem in the
future is important in order to allow clinicians
to make informed decisions. 
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